Results 161 to 170 of about 150,813 (294)

Proteomic profile of CSF obtained at the time of diagnosis determines amyotrophic lateral sclerosis progression and survival: CXCL7 levels in disease prognosis and survival

Brain Pathology, EarlyView.
Untargeted multiomic profiling of cerebrospinal fluid reveals that proteomic, but not lipidomic, signatures robustly distinguish ALS patients from controls and stratify individuals by survival, highlighting marked molecular differences between short survival and long survival disease.
Sergio Roca‐Pereira, Yaiza López‐Sampere, Pol Mengod‐Soler, Mario Peña‐Fonteboa, Carla Marco, Alejandro Caravaca‐Puchades, Raúl Domínguez, Juan Francisco Vázquez‐Costa, Enrique Santamaría, Joaquín Fernández‐Irigoyen, María J. Colomina, Isabel León Moreno, Antonio Martínez Yélamos, Sergio Martínez Yélamos, Gabriel Santpere, Elia Obis, Manuel Portero‐Otín, Gerard Piñol‐Ripoll, Mónica Povedano, Pol Andrés‐Benito   +19 more
wiley   +1 more source

Spontaneous tumor lysis syndrome following liver biopsy: a case report and literature review. [PDF]

Front Oncol
Mao W, Jiang X, Wang M, Cai K, Hu W, Gong S, Zhao Y.   +6 more
europepmc   +1 more source

Spongiosolysis [PDF]

, 1987
Gilbert, P., Stief, Christian Georg
core   +1 more source

Differential segment‐specific signalling pathways for guanylate cyclase C‐activated anion secretion in murine ileocolon

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Guanylate cyclase‐C (GC‐C) is the receptor for endogenous (uro)guanylin peptides, bacterial toxins and pharmacological analogues. Receptor activation leads to intestinal fluid loss, but also activates an antiproliferative pathway and is a promising target in colorectal cancer therapy.
Renjie Xiu, Johannes Reiner, Franz Hofmann, Azam Salari, Ursula Seidler   +4 more
wiley   +1 more source

Successful use of Remcyte®-based continuous hemodiafiltration in a case of refractory CRS and ICANS complicated by tumor lysis syndrome-associated AKI. [PDF]

CEN Case Rep
Yomogida D, Hasegawa S, Mizuta S, Horikawa S, Koshida Y.   +4 more
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

The Use of Single Dose of Rasburicase for the Prophylaxis and Treatment of Tumor Lysis Syndrome in Pediatric Patients: A Narrative Review. [PDF]

Hematol Rep
Lee AC.
europepmc   +1 more source

IRF4 Enhances Radiosensitivity of Cervical Cancer by Inhibiting the PI3K/Akt/mTOR Pathway to Regulate Autophagy

Cancer Science, EarlyView.
IRF4 is a prognostic biomarker in cervical cancer. IRF4 enhances radiosensitivity and inhibits tumor growth via PI3K/AKT/mTOR‐mediated autophagy. IRF4 boosts radiation response in vitro and in vivo. ABSTRACT Interferon regulatory factor 4 (IRF4), a critical member of the IRF transcription factor family, harbors an elusive biological role in cervical ...
Meihui Gao, Zhaolei Cui, Huachun Song, Yanhong Li, Anyang Li, Jianfeng Zheng, Linying Liu, Xuefen Lin, Wankai Fu, Yang Sun   +9 more
wiley   +1 more source

Severe leukemoid reaction and spontaneous tumor lysis syndrome in a young patient with undifferentiated Lynch syndrome-associated ovarian cancer. [PDF]

Gynecol Oncol Rep
Watkins CMS, Allahifard M, Cattoni J, Montemorano L.   +3 more
europepmc   +1 more source

Construction, expression, and characterization of rSEA-EGF and in vitro evaluation of its antitumor activity against nasopharyngeal cancer [PDF]

, 2018
He, Ying, Liu, Xueting, Tao, Ailin, Wang, Shan, Xie, Yang, Zeng, Liping, Zhang, Jianguo, Zhang, Junyan, Zhou, Zhongqiu, Zou, Zehong   +9 more
core   +2 more sources